By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.
The Voice of People With Breast Cancer
Generic Name
Fulvestrant
Brand Name
- Faslodex
- AstraZeneca
- Stage IV (metastatic)
- HR+
- Hormone therapy
- Injectable
- Listed on Provincial/Territorial drug Formulary
The process of getting a drug approved and publicly funded in Canada is complex and lengthy. CBCN has created an infographic on how drugs get funded in Canada to make understanding Canada’s drug approval process a little easier. Access the infographic here.
- Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nunavut, Ontario, Prince Edward Island, Québec, Saskatchewan
- Yes
- Yes
Haven, a Patient Support Program by Sentrex Health Solutions, may provide coverage for this treatment. Access their enrollment form here.
Contact Haven:
Phone: 1-866-352-3211
Email: haven@sentrex.com
Receive updates by email Subscribe Now
About CBCN
CBCN strives to voice the views and concerns of breast cancer patients through education, advocacy activities, and the promotion of information sharing.
Canadian Breast Cancer Network
185 Somerset St. West Suite 318, Ottawa, ON Canada K2P 0J2
Tel: 613-230-3044
Toll-free: 1-800-685-8820
Email Us
